Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Pharmacol ; 168(4): 863-79, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22994368

RESUMO

BACKGROUND AND PURPOSE: Nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor antagonists have been proposed as a novel therapeutic approach to Parkinson's disease. Main limitations of previous studies were the use of structurally similar compounds and the evaluation of their acute effects only. We report here on the acute and long-term antiparkinsonian effects of the novel compound 2-[3-[4-(2-chloro-6-fluoro-phenyl)-piperidin-1-ylmethyl]-2-(morpholine-4-carbonyl)-indol-1-yl]-acetamide (NiK-21273) in comparison with the potent and selective NOP receptor antagonist SB-612111. EXPERIMENTAL APPROACH: Basic pharmacological properties of NiK-21273 were studied in cell lines and isolated tissues (mouse and rat vas deferens). Antiparkinsonian effects were studied in reserpinized mice and 6-hydroxydopamine hemilesioned rats under both acute and chronic administration protocols. KEY RESULTS: In vitro, NiK-21273 behaved as a potent (pA(2) 7.7) and selective NOP receptor antagonist. In vivo, it reduced hypokinesia in reserpinized mice at 0.1 and 1 but not 10 mg·kg(-1), whereas SB-612111 (0.01-1 mg·kg(-1)) provided a dose-dependent antiparkinsonian effect. NiK-21273 ameliorated motor performance in 6-hydroxydopamine hemilesioned rats at 0.5 and 5 but not 15 mg·kg(-1). SB-612111 replicated these effects in the 0.01-1 mg·kg(-1) range without loss of efficacy. Both antagonists synergized with L-DOPA at subthreshold doses. Chronic administration of NiK-21273 provided delayed improvement in baseline activity at 0.5 and 1.5 mg·kg(-1), although tolerance to the higher dose was observed. Conversely, SB-612111 (1 mg·kg(-1)) maintained its effects over time without modifying baseline activity. CONCLUSIONS AND IMPLICATIONS: NOP receptor antagonists provide motor benefit in parkinsonism models although the 'therapeutic' window and long-term effects may vary between compounds.


Assuntos
Antiparkinsonianos/uso terapêutico , Comportamento Animal/efeitos dos fármacos , Cicloeptanos/uso terapêutico , Indóis/uso terapêutico , Antagonistas de Entorpecentes , Transtornos Parkinsonianos/prevenção & controle , Piperidinas/uso terapêutico , Animais , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacologia , Células CHO , Cálcio/metabolismo , Cricetinae , Cricetulus , Cicloeptanos/administração & dosagem , Cicloeptanos/farmacologia , Relação Dose-Resposta a Droga , Indóis/administração & dosagem , Indóis/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos , Atividade Motora/efeitos dos fármacos , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/fisiopatologia , Piperidinas/administração & dosagem , Piperidinas/farmacologia , Ratos , Ratos Sprague-Dawley , Receptores Opioides/genética , Reserpina/farmacologia , Teste de Desempenho do Rota-Rod , Transfecção , Ducto Deferente/efeitos dos fármacos , Receptor de Nociceptina
2.
J Pharmacol Exp Ther ; 335(3): 622-35, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20805306

RESUMO

The novel quaternary ammonium salt (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407) showed subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2), and M3 (hM3) receptors and dissociated very slowly from hM3 receptors (t(½) = 166 min) with a large part of the receptorial complex (54%) remaining undissociated at 32 h from radioligand washout. In contrast, [(3)H]CHF5407 dissociated quickly from hM2 receptors (t(½) = 31 min), whereas [(3)H]tiotropium dissociated slowly from both hM3 (t(½) = 163 min) and hM2 receptor (t(½) = 297 min). In the guinea pig isolated trachea and human isolated bronchus, CHF5407 produced a potent (pIC(50) = 9.0-9.6) and long-lasting (up to 24 h) inhibition of M3 receptor-mediated contractile responses to carbachol. In the guinea pig electrically driven left atrium, the M2 receptor-mediated inhibitory response to carbachol was recovered more quickly in CHF5407-pretreated than in tiotropium-pretreated preparations. CHF5407, administered intratracheally to anesthetized guinea pigs, potently inhibited acetylcholine (Ach)-induced bronchoconstriction with an ED(50) value of 0.15 nmol/kg. The effect was sustained over a period of 24 h, with a residual 57% inhibition 48 h after antagonist administration at 1 nmol/kg. In conscious guinea pigs, inhaled CHF5407 inhibited Ach-induced bronchoconstriction for at least 24 h as did tiotropium at similar dosages. Cardiovascular parameters in anesthetized guinea pigs were not significantly changed by CHF5407, up to 100 nmol/kg i.v. and up to 1000 nmol/kg i.t. In conclusion, CHF5407 shows a prolonged antibronchospastic activity both in vitro and in vivo, caused by a very slow dissociation from M3 receptors. In contrast, CHF5407 is markedly short-acting at M2 receptors, a behavior not shared by tiotropium.


Assuntos
Broncoconstrição/efeitos dos fármacos , Broncodilatadores/farmacologia , Carbamatos/farmacologia , Antagonistas Muscarínicos/farmacologia , Quinuclidinas/farmacologia , Receptor Muscarínico M3/antagonistas & inibidores , Acetilcolina/farmacologia , Idoso , Anestesia , Animais , Pressão Sanguínea/efeitos dos fármacos , Brônquios/efeitos dos fármacos , Espasmo Brônquico/induzido quimicamente , Espasmo Brônquico/tratamento farmacológico , Espasmo Brônquico/prevenção & controle , Broncoconstritores/farmacologia , Broncodilatadores/administração & dosagem , Broncodilatadores/metabolismo , Células CHO , Carbacol/farmacologia , Carbamatos/administração & dosagem , Carbamatos/metabolismo , Cricetinae , Cricetulus , Diaminas/administração & dosagem , Diaminas/farmacologia , Cobaias , Átrios do Coração/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Estrutura Molecular , Antagonistas Muscarínicos/administração & dosagem , Antagonistas Muscarínicos/metabolismo , Contração Miocárdica/efeitos dos fármacos , Quinuclidinas/administração & dosagem , Quinuclidinas/metabolismo , Receptor Muscarínico M1/genética , Receptor Muscarínico M1/metabolismo , Receptor Muscarínico M2/agonistas , Receptor Muscarínico M2/antagonistas & inibidores , Receptor Muscarínico M2/genética , Receptor Muscarínico M2/metabolismo , Receptor Muscarínico M3/agonistas , Receptor Muscarínico M3/genética , Receptor Muscarínico M3/metabolismo , Derivados da Escopolamina/administração & dosagem , Derivados da Escopolamina/metabolismo , Derivados da Escopolamina/farmacologia , Brometo de Tiotrópio , Traqueia/efeitos dos fármacos , Transfecção , Função Ventricular Esquerda/efeitos dos fármacos
3.
J Med Chem ; 44(11): 1675-89, 2001 May 24.
Artigo em Inglês | MEDLINE | ID: mdl-11356103

RESUMO

A stepwise chemical modification from human neurokinin-3 receptor (hNK-3R)-selective antagonists to potent and combined hNK-3R and hNK-2R antagonists using the same 2-phenylquinoline template is described. Docking studies with 3-D models of the hNK-3 and hNK-2 receptors were used to drive the chemical design and speed up the identification of potent and combined antagonsits at both receptors. (S)-(+)-N-(1-Cyclohexylethyl)-3-[(4-morpholin-4-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (compound 25, SB-400238: hNK-3R binding affinity, K(i) = 0.8 nM; hNK-2R binding affinity, K(i) = 0.8 nM) emerged as the best example in this approach. Further studies led to the identification of (S)-(+)-N-(1,2,2-trimethylpropyl)-3-[(4-piperidin-1-yl)piperidin-1-yl]methyl-2-phenylquinoline-4-carboxamide (compound 28, SB-414240: hNK-3R binding affinity, K(i) = 193 nM; hNK-2R binding affinity, K(i) = 1.0 nM) as the first hNK-2R-selective antagonist belonging to the 2-phenylquinoline chemical class. Since some members of this chemical series showed a significant binding affinity for the human mu-opioid receptor (hMOR), docking studies were also conducted on a 3-D model of the hMOR, resulting in the identification of a viable chemical strategy to avoid any significant micro-opioid component. Compounds 25 and 28 are therefore suitable pharmacological tools in the tachykinin area to elucidate further the pathophysiological role of NK-3 and NK-2 receptors and the therapeutic potential of selective NK-2 (28) or combined NK-3 and NK-2 (25) receptor antagonists.


Assuntos
Morfolinas/síntese química , Piperidinas/síntese química , Quinolinas/síntese química , Receptores da Neurocinina-2/antagonistas & inibidores , Receptores da Neurocinina-3/antagonistas & inibidores , Sequência de Aminoácidos , Animais , Células CHO , Clonagem Molecular , Cricetinae , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Morfolinas/química , Morfolinas/metabolismo , Piperidinas/química , Piperidinas/metabolismo , Quinolinas/química , Quinolinas/metabolismo , Ensaio Radioligante , Receptores da Neurocinina-2/química , Receptores da Neurocinina-2/metabolismo , Receptores da Neurocinina-3/química , Receptores da Neurocinina-3/metabolismo , Receptores Opioides mu/química , Receptores Opioides mu/metabolismo , Relação Estrutura-Atividade
4.
Farmaco ; 56(1-2): 117-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11347951

RESUMO

In the last decade a number of selective and potent non-peptidic agents became available to explore the usefulness of the delta-opioid receptor in modulation of pain of different origins. As a continuing effort in this field, potent and selective delta-opioid agonists based on the pyrrolomorphinan framework have been designed, synthesised and characterised biologically in our laboratories. In animal models, a selected compound of interest, SB 235863, has proved the concept that selective delta-opioid agonists may have great potential as pain relief agents in inflammatory and neuropathic pain conditions. Importantly, such a compound was free of the unwanted side effects usually associated with narcotic analgesics such as morphine.


Assuntos
Analgésicos Opioides/farmacologia , Receptores Opioides delta/agonistas , Animais , Desenho de Fármacos , Humanos , Inflamação/tratamento farmacológico , Dor/tratamento farmacológico , Relação Estrutura-Atividade
5.
J Pharmacol Exp Ther ; 292(2): 803-9, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10640321

RESUMO

In this study, the activity of the delta-opioid receptor subtype-selective agonist, SB 227122, was investigated in a guinea pig model of citric acid-induced cough. Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively. The nonselective opioid receptor antagonist, naloxone (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated. The delta-receptor antagonist, SB 244525 (10 mg/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg/kg, i.p.). In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.). The sigma-receptor antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122. These studies provide compelling evidence that the antitussive effects of SB 227122 in this guinea pig cough model are mediated by agonist activity at the delta-opioid receptor.


Assuntos
Tosse/prevenção & controle , Levalorfano/análogos & derivados , Antagonistas de Entorpecentes/farmacologia , Pirróis/uso terapêutico , Receptores Opioides delta/efeitos dos fármacos , Receptores Opioides delta/fisiologia , Animais , Células CHO , Carbazóis/farmacologia , Linhagem Celular , Clonagem de Organismos , Codeína/farmacologia , Cricetinae , Dextrometorfano/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Interações Medicamentosas , Cobaias , Humanos , Hidrocodona/farmacologia , Levalorfano/uso terapêutico , Masculino , Naloxona/farmacologia , Ligação Proteica , Piridinas/farmacologia , Pirrolidinas/farmacologia , Receptores Opioides delta/agonistas , Receptores Opioides kappa/agonistas , Receptores Opioides kappa/efeitos dos fármacos , Receptores Opioides kappa/fisiologia , Receptores Opioides mu/agonistas , Receptores Opioides mu/efeitos dos fármacos , Receptores Opioides mu/fisiologia
6.
Org Lett ; 1(3): 513-5, 1999 Aug 12.
Artigo em Inglês | MEDLINE | ID: mdl-10822591

RESUMO

[formula: see text] Synthesis of four novel thieno derivatives 4-7 featuring the codeine skeletal backbone is reported. Characterization by 1H and 13C NMR is also discussed, along with binding profile for opioid receptors.


Assuntos
Morfinanos/síntese química , Papaver/química , Plantas Medicinais , Linhagem Celular , Humanos , Ligantes , Espectroscopia de Ressonância Magnética , Morfinanos/química , Morfinanos/metabolismo , Receptores Opioides/metabolismo
7.
J Med Chem ; 40(20): 3192-8, 1997 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-9379438

RESUMO

This paper describes the design and synthesis of compounds belonging to a novel class of substituted pyrrolooctahydroisoquinolines which are potent and selective delta opioid agonists. Molecular modeling studies performed on known, selective delta ligands such as (+)-3 and the potent delta agonists SNC 80 led to the identification of the carboxamido moiety of the latter as a putative nonaromatic delta address. Insertion of this moiety onto the octahydroisoquinoline opioid message resulted in (+/-)-5b, a potent and selective delta ligand. The active enantiomer, (-)-5b, displayed nanomolar affinity for the delta receptor (Ki = 0.9 nM) with good mu/delta and kappa/delta binding selectivity ratios (140 and 1480, respectively). In addition, (-)-5b behaved as a full delta agonist in the mouse vas deferens bioassay having an IC50 = 25 nM and being antagonised in the presence of 30 nM naltrindole (NTI). These studies, based on the message-address concept, indicated that the nonaromatic (N,N-diethylamino)carbonyl moiety is a viable alternative to the classical benzene ring as a delta opioid address. Preliminary in vivo studies showed that (+/-)-5b produced a dose-related antinociception in the mouse abdominal constriction test after intracerebroventricular administration (ED50 = 1.6 micrograms/mouse).


Assuntos
Indóis/química , Isoquinolinas/química , Pirróis/química , Receptores Opioides delta/agonistas , Animais , Benzamidas/química , Benzamidas/farmacologia , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Simulação por Computador , Relação Dose-Resposta a Droga , Desenho de Fármacos , Leucina Encefalina-2-Alanina/metabolismo , Indóis/farmacologia , Isoquinolinas/farmacologia , Ligantes , Masculino , Camundongos , Modelos Moleculares , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Nociceptores/efeitos dos fármacos , Piperazinas/química , Piperazinas/farmacologia , Pirróis/farmacologia , Quinolinas/química , Quinolinas/metabolismo , Transdução de Sinais , Estereoisomerismo , Ducto Deferente/efeitos dos fármacos
8.
J Recept Res ; 12(2): 171-80, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1316438

RESUMO

Binding capacities and affinities (KD) of ligands at mu-, delta- and kappa-opioid binding sites were determined by selective labelling techniques together with analysis of saturation curves in seven regions of the guinea-pig brain. The kappa-sites predominated over the other sites in most regions and were 90% of the total in the cerebellum; binding capacities at kappa-sites were highest in the cortex, intermediate in the cerebellum, striatum and mesencephalon and lowest in the diencephalon, hippocampus and pons-medulla. At the mu-sites, binding capacities were highest in the diencephalon and mesencephalon, with intermediate levels in the pons-medulla, cortex and striatum, and low levels in the hippocampus and cerebellum. The highest binding capacity at the delta-sites was in the striatum, intermediate in the cortex, diencephalon and hippocampus, low in the mesencephalon and pons-medulla and not detectable in the cerebellum. No regional differences in binding affinities were found at mu-, delta- and kappa-sites with [3H]-[D-Ala2,MePhe4,Gly-ol5]enkephalin (KD = 1.10-2,61 nM), [3H]-[D-Ala2,D-Leu5]enkephalin (KD = 0.81-1.94 nM) and [3H]-(-)-bremazocine (KD = 0.083-0.185 nM). Thus in guinea-pig brain there are regional differences in opioid binding capacity and in the distribution of mu-, delta- and kappa-sites, but not in binding affinities.


Assuntos
Encéfalo/metabolismo , Receptores Opioides/metabolismo , Animais , Benzomorfanos/metabolismo , Ala(2)-MePhe(4)-Gly(5)-Encefalina , Leucina Encefalina-2-Alanina/metabolismo , Encefalinas/metabolismo , Cobaias , Técnicas In Vitro , Masculino , Receptores Opioides delta , Receptores Opioides kappa , Receptores Opioides mu
9.
J Recept Res ; 12(1): 39-57, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1314311

RESUMO

Binding sites were characterized in rat whole spinal cord crude membrane preparations using selective labelling techniques with multiple methods of mathematical analysis of experimental curves. Mathematical analysis of single [3H]-[D-Ala2,MePhe4,Gly-ol5] enkephalin (DAGO) saturation curves suggested binding of the [3H]-ligand at one site, while displacement curves of low concentrations of [3H]-DAGO with selective mu-ligands indicated the presence of high- and low-affinity sites. All the [3H]-DAGO curves processed simultaneously by LIGAND analysis showed the presence of high (27%) and low (73%) affinity components, with a total Bmax of 3.19 pmol/g tissue. Eighty percent of [3H]-[D-Ala2,D-Leu5] enkephalin (DADLE) binding was displaced by DAGO with high affinity, indicating that a high percentage of [3H]-DADLE binding was at mu-sites. Saturation curves of [3H]-DADLE after inhibition of mu-sites by unlabelled DAGO (delta-sites) were monophasic with non-linear fitting analysis and the Bmax was 0.90 pmol/g tissue. Most mathematical analysis of single saturation curves of [3H]-(-)-bremazocine indicated binding at more than one site. DAGO, DADLE, U-69,593 and PD 117302 displaced 0.15 nM of [3H]-(-)-bremazocine biphasically: the percentages of displacement calculated with the non-linear fitting program were respectively 50 (mu-sites), 64 ((mu + delta)-sites), 18 and 25 (kappa-sites). Haloperidol displaced [3H]-(-)-bremazocine only at microM concentrations. suggesting no binding at sigma-sites. In the presence of 225 nM of DAGO, DADLE displaced only 21% of [3H]-(-)-bremazocine 0.15 nM binding (delta-sites). Most mathematical analysis of saturation curves of [3H]-(-)-bremazocine, after inhibition of binding at mu- and delta-sites by DAGO and DADLE, still indicated binding at more than one site and the selective kappa-ligands U-69,593 and PD 117302 displaced [3H]-(-)-bremazocine in these experimental conditions. LIGAND analysis of saturation and inhibition curves of [3H]-(-)-bremazocine by U-69,593 and PD 117302 showed the presence of high (43%) and low (57%) affinity components, with a total Bmax of 2,73 pmol/g tissue. Thus in rat spinal cord there are at least two mu-sites bound by [3H]-DAGO which amount together to approximately 47% of total opioid sites, delta-sites bound by [3H]-DADLE amounting to approximately 13%, kappa-sites and other unknown sites (possibly a kappa-subtype) bound by [3H]-(-)-bremazocine, which together are approximately 40% of total opioid sites.


Assuntos
Receptores Opioides/análise , Medula Espinal/química , Animais , Benzomorfanos/metabolismo , Sítios de Ligação , Ala(2)-MePhe(4)-Gly(5)-Encefalina , Leucina Encefalina-2-Alanina/metabolismo , Encefalinas/metabolismo , Técnicas In Vitro , Masculino , Ratos
11.
Res Commun Chem Pathol Pharmacol ; 72(3): 295-306, 1991 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1658887

RESUMO

The in vitro binding profile and some in vivo pharmacological properties of (+/-)trans-N-Methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzo[b]-thiophene- 4-acetamide (PD 117302) were tested in rats. In rat brain membrane preparation, PD 117302 was selective for the k-binding sites, its KI (3.51 nM) being respectively about 200 and 1300 times lower at k- than at mu- and delta-sites. In vivo, PD 117302 injected intravenously (i.v.) showed dose-related analgesic effects in the 55 degrees C hot-plate test (peak-time 5 min) and in the paw pressure test. In both tests high doses of naloxone were required for full antagonism. PD 117302, injected i.v., produced dose-related diuresis in normally hydrated rats, which was prevented by 2 mg/kg of subcutaneous naloxone or diprenorphine. PD 117302 at doses between 0.125 and 2 mg/kg i.v. did not delay the gastrointestinal transit of a charcoal meal and did not antagonize morphine-induced constipation. Thus PD 117302 has good selectivity for k-binding sites in vitro and induces analgesia and diuresis, but does not slow gastrointestinal transit in vivo, supporting its k-agonist activity.


Assuntos
Analgesia , Encéfalo/metabolismo , Diprenorfina/farmacologia , Pirróis/farmacologia , Receptores Opioides/metabolismo , Tiofenos/farmacologia , Animais , Sítios de Ligação , Técnicas de Cultura , Diurese/efeitos dos fármacos , Relação Dose-Resposta a Droga , Trânsito Gastrointestinal/efeitos dos fármacos , Injeções Intravenosas , Masculino , Naloxona/farmacologia , Medição da Dor , Pirróis/antagonistas & inibidores , Pirróis/metabolismo , Ratos , Receptores Opioides kappa , Tiofenos/antagonistas & inibidores , Tiofenos/metabolismo
12.
J Pharmacol Exp Ther ; 254(1): 91-7, 1990 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-2164103

RESUMO

The roles of various types of opioid receptors in opioid-induced local inhibition of gastrointestinal transit were studied in rats 5 min after a charcoal meal, injecting i.p. relatively selective agonists and antagonists. The proposed mu agonists, morphine and [D-Ala2,MePhe4,Gly-ol5]enkephalin (DAMGO), and the nonselective delta agonist, [D-Ala2,D-Leu5]enkephalin (DADLE), produced a dose-related inhibition of gastrointestinal transit at the peak time and the i.p. doses producing a 50% reduction of the control values (A50) were 0.015, 0.006 and 0.023 mg/kg, respectively, for morphine, DAMGO and DADLE. The effect of the other nonselective delta agonist, [D-Ser2,L-Leu5]enkephalyl-Thr (DSLET), was not linearly related with the dose. The proposed selective delta agonist, [D-Pen2,D-Pen5]enkephalin (DPDPE), and the selective kappa agonist, U-69,593, up to 2 and 15 mg/kg i.p., respectively, did not delay gastrointestinal transit. Naloxone (0.05 mg/kg i.p.) injected 1 min before each agonist produced a significant parallel shift to the right of the dose-response curves for morphine and DAMGO, but only partly antagonized the effects of DADLE and DSLET. The selective delta antagonist ICI 174,864 (1 mg/kg i.p., injected 1 min before each agonist) shifted the dose-response curve of DADLE, but not of the mu agonists, slightly, but significantly to the right, and had an inconsistent effect on DSLET. Naloxone prevented DADLE's effect on the gut with a nonlinear dose-response curve and much higher doses of naloxone were required to prevent fully DADLE-induced effects than to antagonize doses of morphine equiactive to DADLE on the gut.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Endorfinas/farmacologia , Motilidade Gastrointestinal/efeitos dos fármacos , Receptores Opioides/fisiologia , Animais , Ala(2)-MePhe(4)-Gly(5)-Encefalina , Encefalina Leucina/análogos & derivados , Encefalina Leucina/farmacologia , Leucina Encefalina-2-Alanina , Encefalinas/farmacologia , Masculino , Oligopeptídeos/farmacologia , Ratos , Receptores Opioides delta , Receptores Opioides kappa , Receptores Opioides mu
13.
Eur J Pharmacol ; 166(2): 213-7, 1989 Jul 18.
Artigo em Inglês | MEDLINE | ID: mdl-2551699

RESUMO

The highest maximum binding capacities at the mu-sites of rabbit brain are in the striatum, with intermediate levels in the diencephalon, mesencephalon, cerebellum and cortex and low levels in the pons-medulla and hippocampus. For the delta-site the highest maximum binding capacity is also in the striatum; there are almost equally low levels in the other brain regions. At the kappa-sites the maximum binding capacities are highest in the diencephalon; there are intermediate levels in the cortex and striatum, and low levels in the mesencephalon, cerebellum, hippocampus and pons-medulla. The KD values lack reproducibility; there are no regional variations at the kappa-site as estimated with [3H](-)-bremazocine, but the possibility cannot be excluded that there are regional variations in the KD values for [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin at the mu-site or for [3H][D-Ala2,D-Leu5]enkephalin at the delta-site. It may be important to use saturation analysis in future investigations of the distributions of the binding sites.


Assuntos
Química Encefálica/efeitos dos fármacos , Leucina Encefalina-2-Alanina/análogos & derivados , Receptores Opioides/efeitos dos fármacos , Analgésicos/metabolismo , Analgésicos/farmacologia , Animais , Benzomorfanos/metabolismo , Benzomorfanos/farmacologia , Ligação Competitiva/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Ala(2)-MePhe(4)-Gly(5)-Encefalina , Encefalina Leucina/análogos & derivados , Encefalina Leucina/metabolismo , Encefalina Leucina/farmacologia , Encefalinas/metabolismo , Encefalinas/farmacologia , Técnicas In Vitro , Masculino , Membranas/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Coelhos , Receptores Opioides/metabolismo , Receptores Opioides delta , Receptores Opioides kappa , Receptores Opioides mu
14.
Life Sci ; 42(21): 2079-89, 1988.
Artigo em Inglês | MEDLINE | ID: mdl-3386393

RESUMO

The peripheral activity of the quaternary narcotic antagonist N-methyl levallorphan-methane sulphonate (SR 58002 C) at opioid sites located in the periphery and in the central nervous system (CNS), was studied by different approaches in rats after subcutaneous injection (s.c.). Pretreatment with SR 58002 C 2,8 or 32 mg/kg s.c. 10, 50 or 110 min before buprenorphine consistently reduced buprenorphine in vivo binding only in the small intestinal longitudinal muscle with attached myenteric plexus (MP), whereas naloxone (1 mg/kg s.c.) 10 min before buprenorphine lowered buprenorphine binding in MP and brain (without cerebellum). Plasma levels were not altered by SR 58002 C or naloxone. The same doses of SR 58002 C injected 10, 50 or 110 min before morphine selectively antagonized the inhibition of transit of a charcoal meal along the small intestine (mainly a peripheral effect) induced by the agonist, but did not antagonize morphine-elicited analgesia in the hot-plate test (central effect). Naloxone (1 mg/kg s.c.) injected 10 min before morphine antagonized both agonist effects simultaneously. In morphine-dependent rats SR 58002 C (0.25, 1, 4 and 32 mg/kg s.c.) induced diarrhea, dose-dependently, in most animals within the first 30 min, while jumping, measured in the same rats, occurred in some animals, not dose-dependently, from 60 min on. Naloxone (1 mg/kg s.c.) induced both effects in most rats. These findings suggest that, although SR 58002 C probably penetrates the blood-brain barrier in some morphine-dependent rats, it discriminates peripheral and CNS opioid effects.


Assuntos
Encéfalo/metabolismo , Levalorfano/análogos & derivados , Morfina/antagonistas & inibidores , Animais , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Buprenorfina/metabolismo , Motilidade Gastrointestinal/efeitos dos fármacos , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/metabolismo , Levalorfano/farmacologia , Masculino , Músculo Liso/efeitos dos fármacos , Músculo Liso/metabolismo , Naloxona/farmacologia , Nociceptores/efeitos dos fármacos , Ratos
15.
Life Sci ; 42(3): 293-301, 1988.
Artigo em Inglês | MEDLINE | ID: mdl-2826959

RESUMO

The kappa-opioid compound U-69,593 was studied in rats in vitro in binding assays to assess its selectivity at the single types of opioid sites and in vivo to assess its analgesic activity and effect on intestinal propulsion. In vitro the U-69,593 inhibition curve of [3H]-(-)-bremazocine binding suppressed at mu- and alpha-sites was biphasic and the inhibition constant (Kl) at the high-affinity site (10-18 nM) was two orders of magnitude smaller than the Kl at the low-affinity site. The Kl at mu- and alpha-sites were respectively 3.3 and 8.5 microM. Thus [3H]-(-)-bremazocine, suppressed at mu- and alpha-sites, may still bind more than one site, which U-69,593 might distinguish. In vivo U-69,593 i.p. prolonged the reaction time of rats on a 55 degrees C hot-plate and the dose of naloxone required to antagonize this effect was 40 times the dose that antagonized morphine-induced antinociception, suggesting the involvement of the kappa-receptor. In the intestinal transit test U-69,593 at doses between 0.5 and 15 mg/kg i.p. only slightly slowed intestinal transit of a charcoal meal in rats with no dose-relation; it partly but significantly antagonized morphine-induced constipation. These results suggest that the kappa-type of opioid receptor, with which U-69,593 interacts may induce analgesia, but has no appreciable role in the mechanisms of opioid-induced inhibition of intestinal transit in rats.


Assuntos
Benzenoacetamidas , Encéfalo/metabolismo , Motilidade Gastrointestinal/efeitos dos fármacos , Nociceptores/efeitos dos fármacos , Pirrolidinas/farmacologia , Receptores Opioides/metabolismo , Animais , Benzomorfanos/metabolismo , Sítios de Ligação , Ala(2)-MePhe(4)-Gly(5)-Encefalina , Encefalina Leucina/análogos & derivados , Encefalina Leucina/metabolismo , Leucina Encefalina-2-Alanina , Encefalinas/metabolismo , Técnicas In Vitro , Masculino , Naloxona/farmacologia , Pirrolidinas/antagonistas & inibidores , Ratos , Receptores Opioides/efeitos dos fármacos
16.
Life Sci ; 42(6): 735-43, 1988.
Artigo em Inglês | MEDLINE | ID: mdl-2828802

RESUMO

The D-optimal design, a minimal sample design that minimizes the volume of the joint confidence region for the parameters, was used to evaluate binding parameters in a saturation curve with a view to reducing the number of experimental points without loosing accuracy in binding parameter estimates. Binding saturation experiments were performed in rat brain crude membrane preparations with the opioid mu-selective ligand [3H]-[D-Ala2,MePhe4,Gly-ol5]enkephalin (DAGO), using a sequential procedure. The first experiment consisted of a wide-range saturation curve, which confirmed that [3H]-DAGO binds only one class of specific sites and non-specific sites, and gave information on the experimental range and a first estimate of binding affinity (Ka), capacity (Bmax) and non-specific constant (k). On this basis the D-optimal design was computed and sequential experiments were performed each covering a wide-range traditional saturation curve, the D-optimal design and a splitting of the D-optimal design with the addition of 2 points (+/- 15% of the central point). No appreciable differences were obtained with these designs in parameter estimates and their accuracy. Thus sequential experiments based on D-optimal design seem a valid method for accurate determination of binding parameters, using far fewer points with no loss in parameter estimation accuracy.


Assuntos
Encéfalo/metabolismo , Encefalinas/metabolismo , Receptores Opioides/metabolismo , Animais , Ala(2)-MePhe(4)-Gly(5)-Encefalina , Cinética , Matemática , Modelos Teóricos , Ratos , Relação Estrutura-Atividade
17.
Brain Res ; 436(1): 25-9, 1987 Dec 08.
Artigo em Inglês | MEDLINE | ID: mdl-2825926

RESUMO

Selective lesions of dopamine (DA) neurons of the nucleus accumbens were made in rats by local injections of 6-hydroxydopamine (6-OHDA). Seven days after 6-OHDA, the binding affinities and capacities at mu-, delta- and kappa-opioid binding sites were determined in the nucleus accumbens by selective labelling techniques. 6-OHDA pretreatment caused a significant increase in the number of delta-opioid binding sites (+30%) while the number of mu-, kappa- and total sites was not modified. The affinity at mu-, delta- and kappa-sites was unchanged after 6-OHDA pretreatment.


Assuntos
Hidroxidopaminas/farmacologia , Núcleo Accumbens/metabolismo , Receptores Opioides/metabolismo , Núcleos Septais/metabolismo , Animais , Sítios de Ligação/efeitos dos fármacos , Denervação , Masculino , Núcleo Accumbens/efeitos dos fármacos , Oxidopamina , Ratos , Receptores Opioides/efeitos dos fármacos
18.
Brain Res ; 428(1): 53-8, 1987 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-3815117

RESUMO

With selective labelling techniques and analysis of saturation curves it is shown that in rat brain the concentrations of mu-, delta- and kappa-binding sites increase differentially during postnatal development. There are no changes in the binding affinities. The concentration (pmol/g brain) of kappa-sites are first to reach adult levels, namely between 7 and 14 days after birth. Adult levels of mu-sites are attained between 14 and 21 days after birth. The most striking finding is that development of delta-sites, which are not detectable 3 days after birth by the method used, lags markedly behind that of mu- and kappa-sites. The profile of development in rat brain is compared to that found previously in mouse brain.


Assuntos
Animais Recém-Nascidos/metabolismo , Encéfalo/metabolismo , Endorfinas/metabolismo , Animais , Animais Recém-Nascidos/crescimento & desenvolvimento , Sítios de Ligação , Masculino , Ratos , Ratos Endogâmicos
19.
NIDA Res Monogr ; 75: 520-3, 1986.
Artigo em Inglês | MEDLINE | ID: mdl-2828999

RESUMO

The agonist effects on intestinal transit of relatively selective mu- and delta- ligands, administered intraperitoneally, and their antagonism by the preferentially mu- and delta- antagonists naloxone and ICI 174,864 were studied in rats 5 min after a charcoal meal. The dose-response curves of the preferential mu- ligands morphine and [D-Ala2, MePhe4, Gly-ol5] enkephalin (DAGO) were shifted by naloxone at low doses but not by ICI 174,864. The preferential delta-peptide [D-Pen2, D-Pen5] enkephalin (DPDPE) had no significant agonist activity. [D-Ala2, D-Leu5] enkephalin (DADLE) induced dose-related effects that were weakly antagonized by ICI 174,864 and partly by low-dose naloxone. Thus the inhibition of intestinal transit induced by opioids may depend mainly on the interaction of the agonists at the mu-receptors, while the delta- receptors may play only a secondary role. DADLE agonist effects probably depend on interaction at mu-, delta- and at non-opioid receptors.


Assuntos
Encefalinas/farmacologia , Trânsito Gastrointestinal/efeitos dos fármacos , Receptores Opioides/fisiologia , Animais , Ala(2)-MePhe(4)-Gly(5)-Encefalina , D-Penicilina (2,5)-Encefalina , Encefalina Leucina/análogos & derivados , Encefalina Leucina/farmacologia , Masculino , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Ratos , Ratos Endogâmicos , Receptores Opioides/efeitos dos fármacos , Receptores Opioides delta , Receptores Opioides mu
20.
Neuropeptides ; 5(4-6): 403-6, 1985 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-2860598

RESUMO

The (+) and (-) isomers of tifluadom were assessed in rats for their opioid activities. In vitro (+)-tifluadom was almost equipotent at mu- and kappa- sites and about 10 times less potent at delta-sites: (-)-tifluadom had the same binding spectrum but was 10-20 times less potent. In vivo (+)-tifluadom delayed the hot-plate reaction time; this effect was antagonized by naloxone, but not by Ro 15-1788. (-)-Tifluadom up to 20 mg/kg had no antinociceptive effect. In the intestinal transit test analgesic doses of (+)-tifluadom did not delay the intestinal transit of a charcoal meal in rats and had weak antagonist activity against morphine-induced inhibition of intestinal transit, whereas (-)-tifluadom had neither agonist nor antagonist effect. It thus appears that (+)-and (-)-tifluadom are not selective in vitro and in vivo for one type of opioid binding site/receptor.


Assuntos
Analgésicos Opioides , Benzodiazepinas/farmacologia , Motilidade Gastrointestinal/efeitos dos fármacos , Receptores Opioides/efeitos dos fármacos , Animais , Masculino , Ratos , Receptores Opioides delta , Receptores Opioides kappa , Receptores Opioides mu , Estereoisomerismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...